Aethlon Medical's Hemopurifier® shows positive in vitro binding results for removing cancer patient EVs, supporting planned phase 1 trials.
Aethlon Medical (NASDAQ: AEMD) announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from cancer patient plasma. The study provides pre-clinical evidence for planned phase 1 safety, feasibility, and dose-finding clinical trials of Hemopurifier in patients with solid tumors treated with anti-PD-1 monotherapy, such as Keytruda® or Opdivo®. Interim CEO, James Frakes, stated that this is an important step forward for Aethlon Medical.
May 10, 2024
5 Articles